Novonesis (Novozymes) BNVZMF +2.98%87 EV-to-FCF is 37.11 as of Jul. 03, 2026, which is 9% below its 10-year median of 40.81. GuruFocus rates NVZMF with a GF Score™ of 87/100 and a GF Value™ of $63.09 (Fairly Valued). The stock has 3 warning signs investors should review. Among 920 Chemicals companies, Novonesis (Novozymes) B ranks worse than 66.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novonesis (Novozymes) B's Enterprise Value is $33,454 Mil.
Novonesis (Novozymes) B's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $901 Mil. Therefore, Novonesis (Novozymes) B's EV-to-FCF for today is 37.11.
The historical rank and industry rank for Novonesis (Novozymes) B's EV-to-FCF or its related term are showing as below:
NVZMF'
s EV-to-FCF Range Over the Past 10 Years
Min: 27.69 Med: 40.81 Max: 164.82
Current: 37.06
During the past 13 years, the highest EV-to-FCF of Novonesis (Novozymes) B was 164.82. The lowest was 27.69. And the median was 40.81.
NVZMF's EV-to-FCF is ranked worse than 66.74% of 920
companies
in the Chemicals industry
Industry Median: 22.655
vs NVZMF: 37.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novonesis (Novozymes) B (OTCPK:NVZMF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novonesis (Novozymes) B's PE Ratio (TTM) for today is calculated as:
Novonesis (Novozymes) B's share price for today is $64.90.
Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.487.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B EV-to-FCF vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's EV-to-FCF falls into.
Novonesis (Novozymes) B's current Enterprise Value is $33,454 Mil.
Novonesis (Novozymes) B's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $901 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (NVZMF) has a EV-to-FCF of 37.11 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novonesis (Novozymes) B and its competitors. This is near median its historical median of 40.81. Over the past decade, Novonesis (Novozymes) B's EV-to-FCF has ranged from 27.69 to 164.82. According to the industry distribution chart, Novonesis (Novozymes) B ranks #614 out of 920 companies in the Chemicals industry, placing it in the top 66.7%.
Is Novonesis (Novozymes) B's EV-to-FCF too high?
Novonesis (Novozymes) B's current EV-to-FCF of 37.11 is near median its 10-year median of 40.81. Over the past 10 years, this metric has ranged from a low of 27.69 to a high of 164.82. The Chemicals industry median EV-to-FCF is 22.66. Novonesis (Novozymes) B's value of 37.11 is 63.8% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #614 out of 920 companies in the Chemicals industry, which is below the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's EV-to-FCF compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #614 out of 920 companies for EV-to-FCF. This places Novonesis (Novozymes) B in the lower half of its industry. The industry median EV-to-FCF is 22.66. Novonesis (Novozymes) B's value of 37.11 is 63.8% above this benchmark. Historically, Novonesis (Novozymes) B's own EV-to-FCF has ranged from 27.69 to 164.82 over the past decade. While the company's 10-year median is 40.81 vs. the industry median of 22.66, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Chemicals company?
The median EV-to-FCF among Chemicals companies is 22.66, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current EV-to-FCF of 37.11 is 63.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median EV-to-FCF is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current EV-to-FCF is 37.11, which is near median its own 10-year median of 40.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $63.09, compared to a current price of $64.90 — trading 2.9% above its estimated fair value. The current EV-to-FCF is 37.11, which is near median its 10-year median of 40.81 and 63.8% above the Chemicals industry median of 22.66. Novonesis (Novozymes) B's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current EV-to-FCF is 37.11 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $64.90 is trading 2.9% above its estimated GF Value™ of $63.09.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMF:
EV-to-FCF: 37.11 (near median its 10-year median of 40.81)
GF Value™: $63.09 vs. price of $64.90 (2.9% above fair value)
Industry Position: 63.8% above the Chemicals median (#614 of 920)
No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
87GF Score
Get the complete analysis for NVZMF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMF has been successfully added to your 
